Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 6, 2021; 9(19): 5266-5269
Published online Jul 6, 2021. doi: 10.12998/wjcc.v9.i19.5266
COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report
Yi-Feng Wu, Wan-Jun Yu, Yu-Hua Jiang, Yin Chen, Bo Zhang, Rui-Bing Zhen, Jun-Tao Zhang, Yi-Ping Wang, Qiang Li, Feng Xu, Yan-Jun Shi, Xian-Peng Li
Yi-Feng Wu, Department of Hepatobiliary and Pancreas Surgery, The Affiliated People’s Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China
Wan-Jun Yu, Rui-Bing Zhen, Department of Respiratory Disease and Critical Care Medicine, The Affiliated People’s Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China
Yu-Hua Jiang, Yin Chen, Bo Zhang, Xian-Peng Li, Department of Infectious Diseases, The Affiliated People’s Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China
Jun-Tao Zhang, Department of Ophthalmology, The Affiliated People’s Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China
Yi-Ping Wang, Department of Laboratory Medicine, The Affiliated People’s Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China
Qiang Li, Department of Radiology, The Affiliated People’s Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China
Feng Xu, Department of Gastroenterology, The Affiliated People’s Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China
Yan-Jun Shi, Department of Hepatobiliary and Pancreas Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou 315009, Zhejiang Province, China
Author contributions: Wu YF, Yu WJ, Jiang YH, Chen Y, Zhang B, Zhen RB, Zhang JT, Wang YP, Li Q, Xu F, and Shi YJ cared for the patient; Wu YF and Li XP reviewed the literature and were primarily responsible for writing the manuscript; Li XP critically reviewed and edited the manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to report.
CARE Checklist (2016) statement: The authors have read the CARE Checklist, and the manuscript was prepared and revised according to the CARE Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xian-Peng Li, MD, PhD, Chief Doctor, Department of Infectious Diseases, The Affiliated People’s Hospital of Ningbo University, No. 251 Baizhang Road, Ningbo 315040, Zhejiang Province, China. rmlixianpeng@nbu.edu.cn
Received: February 3, 2021
Peer-review started: February 3, 2021
First decision: February 28, 2021
Revised: March 3, 2021
Accepted: May 15, 2021
Article in press: May 15, 2021
Published online: July 6, 2021
Abstract
BACKGROUND

Since the initial recognition of coronavirus disease 2019 (COVID-19) in Wuhan, this infectious disease has spread to most areas of the world. The pathogenesis of COVID-19 is yet unclear. Hepatitis B virus (HBV) reactivation occurring in COVID-19 patients has not yet been reported.

CASE SUMMARY

A 45-year-old hepatitis B man with long-term use of adefovir dipivoxil and entecavir for antiviral therapy had HBV reactivation after being treated with methylprednisolone for COVID-19 for 6 d.

CONCLUSION

COVID-19 or treatment associated immunosuppression may trigger HBV reactivation.

Keywords: COVID-19, Hepatitis B virus, Reactivation, Diagnose, Therapy, Case report

Core Tip: In this study, the authors found that coronavirus disease 2019 or treatment associated immunosuppression may trigger hepatitis B virus reactivation.